CT0181

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameCT0181
Drug Alias NameCT0181 humanized anti GPC3 autogenous T Cell injectionAn autologous T cell product targeting GPC3 antibody fused to T cell receptor and co-expressing IL-7 cytokine (Carsgen)CT-0181
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitorsInterleukin-7 receptors agonists
TargetsGlypican-3Interleukin-7 receptors
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPeking UniversityCarsgen Biomedicine (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A